Australia · Delayed Price · Currency is AUD PYC Therapeutics Company Description
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11.
The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019.
PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
| Country | Australia |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Rohan Hockings |
Contact Details
Address: Harry Perkins Institute of Medical Research Nedlands, Washington 6009 Australia | |
| Phone | 61 8 6151 0992 |
| Website | pyctx.com |
Stock Details
| Ticker Symbol | PYC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PYC7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | Chief Executive Officer and Executive Director |
| Thomas Ulmer | Chief Financial Officer |
| Garrett Bray | Chief Operating Officer |
| Dr. Janya Grainok | Chief Scientific Officer |
| Jonathan Riley B.Sc., L.L.B. | General Counsel and Joint Company Secretary |
| Dr. Paula Cunningham | Chief Development Officer |
| Candice Junge | Chief Clinical Development Officer |
| Stephen Alan Ledger B.Com. | Joint Company Secretary |